Structure of the has operon promoter and the effect of mutations on the has promoter strength in Streptococcus equi subsp. zooepidemicus
Language English Country Switzerland Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Genes, Bacterial genetics MeSH
- Bacterial Proteins MeSH
- Glucuronidase MeSH
- Cloning, Molecular MeSH
- Molecular Sequence Data MeSH
- Mutation genetics MeSH
- Mutagenesis MeSH
- Operon MeSH
- Plasmids MeSH
- Promoter Regions, Genetic genetics MeSH
- Base Sequence MeSH
- Sequence Alignment MeSH
- Streptococcus equi genetics MeSH
- Streptococcus pyogenes genetics MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Bacterial Proteins MeSH
- Glucuronidase MeSH
The purpose of this study is to determine the effect of the corresponding nucleotides from Streptococcus pyogenes on the has promoter strength in highly encapsulated strain S. equi subsp. zooepidemicus (SEZ) and detect an empowering mutations in SEZ. Eight different strains of SEZ carrying nucleotide mutations in the -73 to -38 region upstream of the has promoter were constructed. The significant activity decrease to 36-1% was observed after the introduction of mutations in the promoter region from -44 to -38 site. The exception was observed in mutation in -49 site when no significant decrease was observed. When nucleotides TTT were used in positions -73 the promoter became weaker, whereas no significant effect was observed after using nucleotides CCC (96%). Unfortunately, introduction of these mutations into chromosome SEZ has no empowering effect. Six strains, which carried nucleotide sequences of different lengths upstream from the transcription start of hasA promoter, were constructed to determine the minimum upstream region required for the maximum transcription efficiency of the has operon. No change of the activity of the has promoter constructs containing as few as 101 nucleotides upstream from the transcription start point was observed.
See more in PubMed
FASEB J. 1992 Apr;6(7):2397-404 PubMed
Infect Immun. 1996 Feb;64(2):503-10 PubMed
Infect Immun. 1997 Apr;65(4):1422-30 PubMed
Lancet. 1994 Oct 22;344(8930):1111-5 PubMed
JAMA. 1993 Jan 20;269(3):384-9 PubMed
Mol Microbiol. 1990 Jul;4(7):1143-52 PubMed
J Biosci Bioeng. 2005 Jun;99(6):521-8 PubMed
Nucleic Acids Res. 1983 Apr 25;11(8):2237-55 PubMed
Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12238-42 PubMed
J Biol Chem. 1993 Apr 5;268(10):7118-24 PubMed
Infect Immun. 1997 Jan;65(1):64-71 PubMed
J Biol Chem. 1987 Oct 5;262(28):13654-61 PubMed
Infect Immun. 1994 Feb;62(2):433-41 PubMed
J Biol Chem. 1994 Jan 7;269(1):169-75 PubMed
J Biol Chem. 1995 Aug 4;270(31):18452-8 PubMed
Anal Biochem. 1976 May 7;72:248-54 PubMed
Clin Infect Dis. 1995 Nov;21(5):1220-7 PubMed
Appl Microbiol Biotechnol. 2005 Jan;66(4):341-51 PubMed
Appl Microbiol Biotechnol. 2007 Apr;74(5):1016-22 PubMed
EMBO J. 1990 Jul;9(7):2215-20 PubMed
J Biol Chem. 1993 Sep 15;268(26):19181-4 PubMed
J Bacteriol. 1995 Nov;177(22):6619-24 PubMed
Med Microbiol Immunol. 1996 May;185(1):11-7 PubMed
J Mol Evol. 2008 Jul;67(1):13-22 PubMed
J Clin Invest. 1996 Nov 1;98(9):1954-8 PubMed
Mol Microbiol. 1998 Apr;28(2):343-53 PubMed
Equine Vet J. 1989 Sep;21(5):351-3 PubMed
J Infect Dis. 1992 Aug;166(2):374-82 PubMed
N Engl J Med. 1989 Jul 6;321(1):1-7 PubMed
Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8317-21 PubMed
Production of hyaluronic acid by mutant strains of group C Streptococcus
